Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

India firm on ‘NO’ to data exclusivity (SiNApSE) (Generic Pharmaceuticals and IP) (Spicy IP) (Spicy IP)

US: CAFC hears oral arguments on patentability of DNA claims: American Molecular Pathology, et. al, v. U.S. Patent and Trademark Office, et. al. (KEI) (Patently-O) (The Prior Art) (Patent Law Practice Center) (EFF) (Patent Docs)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

The Hinxton Group foresees stem cell issues and proposes solutions (Patent Docs)

FAO Seed Treaty carries hope, addressing country contributions, farmers concerns (IP Watch)

Australia provides for developing countries in need of pharmaceuticals (IP Whiteboard)

Belgium: Supreme Court upholds confidentiality measures in Novartis v. GSK Biologicals (EPLAW)

France: Cour de cassation decision in case for infringement of European patent relating to ‘cloned DNA sequences, hybridizable with genomic RNA of the LAV’: Institut Pasteur v. Chiron Healthcare & Novartis (EPLAW)

India firm on ‘NO’ to data exclusivity (SiNApSE) (Generic Pharmaceuticals and IP) (Spicy IP) (Spicy IP)

US: CAFC hears oral arguments on patentability of DNA claims: American Molecular Pathology, et. al, v. U.S. Patent and Trademark Office, et. al. (KEI) (Patently-O) (The Prior Art) (Patent Law Practice Center) (EFF) (Patent Docs)

US farmers sue Monsanto over GMO patents, demand right to conventional crops (IP Watch) (IP Biz)

US: BIO commends launch of House patent reform process: Expresses concern with inter partes review changes (PatentlyBIOtech)

US: Oncolytics files for correction of PTA calculation for ‘Reoviruses having modified sequences’ patent (Patent Docs)

Products

Akatinol (Memantine) – EU: AG offers alternative solutions in Sython reference: Case C‑195/09 Synthon BV v Merz Pharma GmbH & Co KG (The SPC Blog)

Amrix (Cyclobenzaprine) – US: Eurand files patent infringement complaint against Anchen in response to Para IV certification (Patent Docs)

Asacol (Mesalamine) – US: NJ District Court punts in Asacol DJ action to trigger 180-day exclusivity forfeiture; Rules that subsequent ANDA applicant lacks standing: Medeva Pharma Suisse v Par Pharmaceuticals (FDA Law Blog)

Cialis (Tadalafil) – Israel: Deja vu all over again – Deputy Commissioner’s reach exceeds his grasp – opposition to Lilly Icos’ patent (America-Israel Patent Law)

Fentora (Fentanyl) – US: Cephalon’s Fentora patent found valid, infringed by Watson (Patent Docs)

Focalin (Dexmethylphenidate) – US: Celgene and Elan file separate patent infringement complaints against Intellipharmaceutics following Para IV certification filing (Patent Docs)

Cubicin (Daptomycin) – US: Cubist Pharmaceuticals settles Cubicin patent litigation with Teva (GenericsWeb)

Gabapentin – Spain: Supreme Court finds infringement of Goedecke’s patent relating to Gabapentin: Goedecke & Pfizer v. Laboratorios Rubió (EPLAW)

Gemzar (Gemcitabine) – US: ITC: Target date of 23 July 2012 set in Certain Gemcitabine (ITC 337 Law Blog)

 Intuniv (Guanfacine) – US: Shire files patent infringement complaint based on Mylan’s ANDA filing (Patent Docs)

Isentress (Raltegravir) – India: Cipla files for compulsory license against Merck’s Isentress (Spicy IP)

Losartan, HCTZ – France: Cour d’appel confirms combination products infringe mono-SPCs and sets precedent on requirements for obtaining a paediatric extension: Du Pont – Merck v Mylan (The SPC Blog)

Lovaza (Omega-3) – US: Pronova settles with Apotex in Lovaza patent dispute (Patent Docs) (GenericsWeb)

Marvelon / Mercilon (Ethinylestradiol) – Finland: Repackaging of pharmaceutical products in parallel: NV Organon v Paranova Oy (JIPLP)

Naropin (Ropivacaine) – US: New federal law of patent assignment: Abraxis Bioscience v Navinta (Property intangible)

OxyContin (Oxycodone) – US: Purdue files lawsuits against Andrx, Actavis Watson and Teva in response to Para IV certification (Patent Docs)

Paroxetine – US: Noven files for PTA correction for ‘Crystalline Paroxetine Methane Sulfonate’ patent (Patent Docs)

Prezista (Darunavir) – US: Tibotec files patent infringement complaint against Hetero Drugs in response to Para IV challenge (Patent Docs)

Prezista (Darunavir) – US: USA, University of Illinois file patent infringement complaint against Hetero Drugs in response to Para IV challenge (Patent Docs)

Reminyl (Galantamine) – EU: AG advises recognition of ancient authorisations: Case C‑427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog)

Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs)

Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog)

Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive patent lawsuit brought by Gedeon Richter (Generic Pharmaceuticals and IP)

Zemplar (Paricalcitol) – US: Abbott Laboratories and WARF settle Zemplar patent suit with Anchen Pharmaceuticals (Patent Docs)

Zymaxid (Gatifloxacin) – US: Senju files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs)